SuperworthAquestive Therapeutics profit margin AQST
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- n/m
- not a meaningful number
- Operating margin, 12 months
- −97.5%
- Peer median
- 11.6%
Aquestive Therapeutics' net margin works out at −145% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | 58.3% |
| FY2024 | −76.7% | −53.5% | 69.0% |
| FY2023 | −15.6% | −29.9% | 58.8% |
| FY2022 | n/a | −88.2% | 59.3% |
| FY2021 | n/a | −68.2% | n/a |
| FY2020 | n/a | −93.6% | 71.7% |
| FY2019 | n/a | n/a | 61.3% |
| FY2018 | −91.0% | −72.6% | n/a |
| FY2017 | −13.4% | −0.2% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | −97.5% | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q1 FY25 | n/a | n/a | −75.9% | |
| Q4 FY24 | −76.7% | −61.1 pts | −53.5% | |
| Q3 FY24 | −59.8% | −34.6 pts | −35.8% | |
| Q2 FY24 | −44.1% | +4.5 pts | −26.0% | |
| Q1 FY24 | −55.9% | +15.3 pts | −37.8% | |
| Q4 FY23 | −15.6% | n/a | −29.9% | |
| Q3 FY23 | −25.2% | n/a | −45.6% |
Against its peers
Companies in Drug Manufacturers - General nearest Aquestive Therapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| AQSTAquestive Therapeutics | n/m |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| NATRNatures Sunshine Products | 3.7% |
| OMEROmeros | n/m |
| Peer median | 11.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Aquestive Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.